CAR-T cells and allogeneic hematopoietic stem cell transplantation for relapsed/refractory B-cell acute lymphoblastic leukemia.

Relapsed/refractory acute lymphoblastic leukemia (ALL) has a low remission rate after chemotherapy, a high relapse rate and poor long-term survival even when allogeneic hematopoietic stem cell transplantation (allo-HSCT) is performed. Chimeric antigen receptors redirected T cells (CAR-T cells) can enhance disease remission with a favorable outcome for relapsed/refractory ALL, though some cases quickly relapsed after CAR-T cell treatment. Thus, treatment with CAR-T cells followed by allo-HSCT may be the best way to treat relapsed/refractory ALL. In this review, we first discuss the different types of CAR-T cells. We then discuss the treatment of relapsed/refractory ALL using only CAR-T cells. Finally, we discuss the use of CAR-T cells, followed by allo-HSCT, for the treatment of relapsed/refractory ALL.

• Publication year

  2017

• Venue

  Immunotherapy

• Publication date

  2017-10-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.2217/imt-2017-0072PMID 29032733
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Genetically enhanced T lymphocytes and the intensive care unit

  2018cited by this paper
• CAR-T bridging to allo-HSCT as a treatment strategy for relapsed adult acute B-lymphoblastic leukemia: a case report

  2018cited by this paper
• Engineering CAR-T cells

  2017cited by this paper
• Donor origin CAR T cells: graft versus malignancy effect without GVHD, a systematic review.

  2017cited by this paper
• New development in CAR-T cell therapy

  2017cited by this paper
• Allogeneic CD19-CAR-T cell infusion after allogeneic hematopoietic stem cell transplantation in B cell malignancies

  2017cited by this paper
• Current status of chimeric antigen receptor therapy for haematological malignancies

  2016cited by this paper
• Making Better Chimeric Antigen Receptors for Adoptive T-cell Therapy

  2016cited by this paper
• Analysis of non-relapse mortality and causes of death over 15 years following allogeneic hematopoietic stem cell transplantation

  2016cited by this paper
• Identification of Predictive Biomarkers for Cytokine Release Syndrome after Chimeric Antigen Receptor T-cell Therapy for Acute Lymphoblastic Leukemia.

  2016cited by this paper
• CD19 CAR-T cells of defined CD4+:CD8+ composition in adult B cell ALL patients.

  2016cited by this paper
• 嵌合抗原受体T细胞治疗儿童急性B淋巴细胞白血病异基因造血干细胞移植后复发一例报告并文献复习

  2016cited by this paper
• Global Manufacturing of CAR T Cell Therapy

  2016cited by this paper
• Predominant cerebral cytokine release syndrome in CD19-directed chimeric antigen receptor-modified T cell therapy

  2016cited by this paper
• Co-infusion of haplo-identical CD19-chimeric antigen receptor T cells and stem cells achieved full donor engraftment in refractory acute lymphoblastic leukemia

  2016cited by this paper
• Distinct Signaling of Coreceptors Regulates Specific Metabolism Pathways and Impacts Memory Development in CAR T Cells.

  2016cited by this paper
• T Cells Expressing CD19/CD20 Bispecific Chimeric Antigen Receptors Prevent Antigen Escape by Malignant B Cells

  2016cited by this paper
• Allogeneic T Cells That Express an Anti-CD19 Chimeric Antigen Receptor Induce Remissions of B-Cell Malignancies That Progress After Allogeneic Hematopoietic Stem-Cell Transplantation Without Causing Graft-Versus-Host Disease.

  2016cited by this paper
• Combination of Anti-CD123 and Anti-CD19 Chimeric Antigen Receptor T Cells for the Treatment and Prevention of Antigen-Loss Relapses Occurring after CD19-Targeted Immunotherapies

  2015cited by this paper
• T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: a phase 1 dose-escalation trial.

  2015cited by this paper
• Identification of Chimeric Antigen Receptors That Mediate Constitutive or Inducible Proliferation of T Cells

  2015cited by this paper
• Chimeric antigen receptor-modified T cells derived from defined CD8+ and CD4+ subsets confer superior antitumor reactivity in vivo

  2015cited by this paper
• Tolerance and efficacy of autologous or donor-derived T cells expressing CD19 chimeric antigen receptors in adult B-ALL with extramedullary leukemia

  2015cited by this paper
• Efficiency of CD19 chimeric antigen receptor-modified T cells for treatment of B cell malignancies in phase I clinical trials: a meta-analysis

  2015cited by this paper
• 4-1BB Costimulation Ameliorates T Cell Exhaustion Induced by Tonic Signaling of Chimeric Antigen Receptors

  2015cited by this paper
• Antileukemic potency of CD19-specific T cells against chemoresistant pediatric acute lymphoblastic leukemia.

  2015cited by this paper
• CD19-targeted chimeric antigen receptor T-cell therapy for acute lymphoblastic leukemia.

  2015cited by this paper
• Donor-derived CD19-targeted T cells in allogeneic transplants

  2015cited by this paper
• Performance-enhancing drugs: design and production of redirected chimeric antigen receptor (CAR) T cells

  2015cited by this paper
• Chimeric antigen receptor T cells for ALL.

  2015cited by this paper
• CAR T-Cell Therapy: The Role of Physical Barriers and Immunosuppression in Lymphoma

  2015cited by this paper
• Time to improve health-related quality of life outcomes in patients with acute promyelocytic leukemia.

  2015cited by this paper
• TRUCKs: the fourth generation of CARs

  2015cited by this paper
• Immunotherapy with CD19-specific chimeric antigen receptor (CAR)-modified T cells of defined subset composition.

  2015cited by this paper
• Chimeric Antigen Receptor 4SCAR19-Modified T Cells in Acute Lymphoid Leukemia: a Phase II Multi-Center Clinical Trial in China

  2015cited by this paper
• Preclinical Development of Bispecific Chimeric Antigen Receptor Targeting Both CD19 and CD22

  2015cited by this paper
• Durable Remissions in Children with Relapsed/Refractory ALL Treated with T Cells Engineered with a CD19-Targeted Chimeric Antigen Receptor (CTL019)

  2015cited by this paper
• Implications of Minimal Residual Disease Negative Complete Remission (MRD-CR) and Allogeneic Stem Cell Transplant on Safety and Clinical Outcome of CD19-Targeted 19-28z CAR Modified T Cells in Adult Patients with Relapsed, Refractory B-Cell ALL

  2015cited by this paper
• Chimeric antigen receptor T cells persist and induce sustained remissions in relapsed refractory chronic lymphocytic leukemia

  2015cited by this paper
• CD19-redirected chimeric antigen receptor-modified T cells: a promising immunotherapy for children and adults with B-cell acute lymphoblastic leukemia (ALL)

  2015cited by this paper
• Chemotherapy-refractory diffuse large B-cell lymphoma and indolent B-cell malignancies can be effectively treated with autologous T cells expressing an anti-CD19 chimeric antigen receptor.

  2015cited by this paper
• Chimeric antigen receptor T cells: power tools to wipe out leukemia and lymphoma

  2015cited by this paper
• Efficacy and Toxicity Management of 19-28z CAR T Cell Therapy in B Cell Acute Lymphoblastic Leukemia

  2014cited by this paper
• Chimeric antigen receptor T-cell therapy for ALL.

  2014cited by this paper
• Chimeric antigen receptor modified T cell therapy for B cell malignancies

  2014cited by this paper
• Chimeric antigen receptor T cells for sustained remissions in leukemia.

  2014cited by this paper
• ICOS-based chimeric antigen receptors program bipolar TH17/TH1 cells.

  2014cited by this paper
• CD19-Targeted T Cells Rapidly Induce Molecular Remissions in Adults with Chemotherapy-Refractory Acute Lymphoblastic Leukemia

  2013cited by this paper
• Chimeric antigen receptor-modified T cells for acute lymphoid leukemia.

  2013cited by this paper
• The myth of the second remission of acute leukemia in the adult.

  2013cited by this paper
• Combining a CD20 Chimeric Antigen Receptor and an Inducible Caspase 9 Suicide Switch to Improve the Efficacy and Safety of T Cell Adoptive Immunotherapy for Lymphoma

  2013cited by this paper
• Infusion of donor-derived CD19-redirected virus-specific T cells for B-cell malignancies relapsed after allogeneic stem cell transplant: a phase 1 study.

  2013cited by this paper
• Donor-derived CD19-targeted T cells cause regression of malignancy persisting after allogeneic hematopoietic stem cell transplantation.

  2013cited by this paper
• Relapsed childhood acute lymphoblastic leukaemia.

  2013cited by this paper
• Gene-engineered T cells for cancer therapy

  2013cited by this paper
• Where do we stand in the treatment of relapsed acute lymphoblastic leukemia?

  2012cited by this paper
• Outcomes after induction failure in childhood acute lymphoblastic leukemia.

  2012cited by this paper
• CD20-specific adoptive immunotherapy for lymphoma using a chimeric antigen receptor with both CD28 and 4-1BB domains: pilot clinical trial results.

  2012cited by this paper
• Combinatorial antigen recognition with balanced signaling promotes selective tumor eradication by engineered T cells

  2012cited by this paper
• CD27 costimulation augments the survival and antitumor activity of redirected human T cells in vivo.

  2012cited by this paper
• Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia.

  2011cited by this paper
• Inducible apoptosis as a safety switch for adoptive cell therapy.

  2011cited by this paper
• CD28 costimulation improves expansion and persistence of chimeric antigen receptor-modified T cells in lymphoma patients.

  2011cited by this paper
• In vivo persistence, tumor localization, and antitumor activity of CAR-engineered T cells is enhanced by costimulatory signaling through CD137 (4-1BB).

  2011cited by this paper
• T Cells with Chimeric Antigen Receptors Have Potent Antitumor Effects and Can Establish Memory in Patients with Advanced Leukemia

  2011cited by this paper
• NCI First International Workshop on the Biology, Prevention, and Treatment of Relapse after Allogeneic Hematopoietic Stem Cell Transplantation: Report from the Committee on Treatment of Relapse after Allogeneic Hematopoietic Stem Cell Transplantation.

  2010cited by this paper
• Adoptive transfer of syngeneic T cells transduced with a chimeric antigen receptor that recognizes murine CD19 can eradicate lymphoma and normal B cells.

  2010cited by this paper
• Cytokine-induced killer cells for cell therapy of acute myeloid leukemia: improvement of their immune activity by expression of CD33-specific chimeric receptors

  2010cited by this paper
• Role of donor lymphocyte infusions in relapsed hematological malignancies after stem cell transplantation revisited.

  2010cited by this paper
• Role of antithymocyte globulin and granulocyte-colony stimulating factor-mobilized bone marrow in allogeneic transplantation for patients with hematologic malignancies.

  2009cited by this paper
• Chimeric receptors containing CD137 signal transduction domains mediate enhanced survival of T cells and increased antileukemic efficacy in vivo.

  2009cited by this paper
• DNA bar coding and pyrosequencing to analyze adverse events in therapeutic gene transfer

  2008cited by this paper
• CD28 costimulation provided through a CD19-specific chimeric antigen receptor enhances in vivo persistence and antitumor efficacy of adoptively transferred T cells.

  2006cited by this paper
• Chimeric Fv-zeta or Fv-epsilon receptors are not sufficient to induce activation or cytokine production in peripheral T cells.

  2000cited by this paper
• Design of retroviral vectors and helper cells for gene therapy.

  2000cited by this paper
• Chimeric Fv-ζ or Fv-ε receptors are not sufficient to induce activation or cytokine production in peripheral T cells

  2000cited by this paper
• A Third-Generation Lentivirus Vector with a Conditional Packaging System

  1998cited by this paper

• Novel CD19 Fast-CAR-T cells vs. CD19 conventional CAR-T cells for the treatment of relapsed/refractory CD19-positive B-cell acute lymphoblastic leukemia

  2025cites this paper
• CAR-T therapy and allogeneic stem cell transplantation for refractory acute myeloid leukemia: A comparative study

  2025cites this paper
• Dynamics modeling of urban rail vehicle axle-box bearings with roller defect considering time-varying impact

  2024cites this paper
• Advanced Targeted Drug Delivery of Bioactive Agents Fortified with Graft Chitosan in Management of Cancer: A Review.

  2024cites this paper
• Skidding characteristics of urban rail vehicle axle-box bearings considering surface waviness on races

  2023cites this paper
• The role of MSCs and CAR-MSCs in cellular immunotherapy

  2023cites this paper
• Advancing CART therapy for acute myeloid leukemia: recent breakthroughs and strategies for future development

  2023cites this paper
• NKG2D-CAR memory T cells target pediatric T-cell acute lymphoblastic leukemia in vitro and in vivo but fail to eliminate leukemia initiating cells

  2023cites this paper
• Quartic CAR-T Cell Bridging to Twice Allo-HSCT Therapy in a Patient with Acute Lymphoblastic Leukemia

  2023cites this paper
• Novel CD19 chimeric antigen receptor T cells manufactured next-day for acute lymphoblastic leukemia

  2022cites this paper
• 免疫靶向治疗在复发/难治性急性B淋巴细胞白血病患者中的疗效分析

  2022cites this paper
• Microbial L-asparaginase as a promising enzyme for treatment of various cancers

  2022cites this paper
• Emerging Management Approach for the Adverse Events of Immunotherapy of Cancer

  2022cites this paper
• Anti-CD19 CAR-T cell therapy bridge to HSCT decreases the relapse rate and improves the long-term survival of R/R B-ALL patients: a systematic review and meta-analysis

  2021cites this paper
• CAR19/22 T cell therapy in adult refractory Burkitt’s lymphoma

  2021cites this paper
• CD19 CAR-T cell treatment conferred sustained remission in B-ALL patients with minimal residual disease

  2021cites this paper
• An owner's manual for CD19 "CAR"-T cell therapy in managing pediatric and young adult B-cell acute lymphoblastic leukemia.

  2021cites this paper
• Successful continuation of clozapine treatment during hematopoietic stem cell transplantation: A step toward health equity in the oncologic care of people with severe mental illness

  2021cites this paper
• Mechanisms underlying CD19-positive ALL relapse after anti-CD19 CAR T cell therapy and associated strategies

  2020cites this paper
• Low Level Donor Chimerism of CD19 CAR-T Cells Returned to Complete Donor Chimerism in Patients with Relapse After Allo-Hematopoietic Stem Cell Transplant

  2020cites this paper
• Donor-derived CD19 CAR-T cell therapy of relapse of CD19-positive B-ALL post allotransplant

  2020cites this paper
• Targeting tumor-associated macrophages for cancer immunotherapy.

  2020cites this paper
• 抗CD19 CAR-T细胞序贯异基因造血干细胞移植术治疗难治B淋巴细胞白血病疗效及安全性观察

  2020cites this paper
• OTT_A_277146 11471..11484

  2020cites this paper
• Anti-leukemic activity of semisynthetic derivatives of lupeol

  2020cites this paper
• Chimeric antigen receptor T‐cell therapy as a bridge to haematopoietic stem cell transplantation for refractory/relapsed B‐cell acute lymphoblastic leukemia

  2019cites this paper
• Use of chimeric antigen receptor T cells in allogeneic hematopoietic stem cell transplantation.

  2019cites this paper
• Cardiovascular Events Among Adults Treated With Chimeric Antigen Receptor T-Cells (CAR-T).

  2019cites this paper
• Diagnosis and Management of Immune Related Adverse Events (irAEs) in Cancer Immunotherapy.

  2019cites this paper
• Treatment Selection for Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia in the Era of Tyrosine Kinase Inhibitors

  2019cites this paper
• Identification of leukemia stem cell expression signatures through Monte Carlo feature selection strategy and support vector machine

  2019cites this paper
• Study on the Prognostic Value of Aberrant Antigen in Patients With Acute B Lymphocytic Leukemia.

  2019cites this paper
• CAR-T bridging to allo-HSCT as a treatment strategy for relapsed adult acute B-lymphoblastic leukemia: a case report

  2018cites this paper
• Gestion des toxicités des lymphocytes T exprimant un récepteur à l’antigène chimérique (CAR-T cells)

  2018cites this paper
• Allogreffe : nouveautés et perspectives

  2018cites this paper
• Genetically enhanced T lymphocytes and the intensive care unit

  2018cites this paper
• Allogreffe : nouveautés et perspectives

  2018cites this paper
• Donor-derived CAR-T Cells Serve as a Reduced-intensity Conditioning Regimen for Haploidentical Stem Cell Transplantation in Treatment of Relapsed/Refractory Acute Lymphoblastic Leukemia: Case Report and Review of the Literature

  2018cites this paper
• Tisagenlecleucel for the treatment of B-cell acute lymphoblastic leukemia

  2018cites this paper